What is the size of the CAR-T Cell Therapies market in 2023?

The CAR-T Cell Therapies market size is USD 2.8 billion in 2023.

What is the projected CAGR at which the CAR-T Cell Therapies market is expected to grow at?

The CAR-T Cell Therapies market is expected to grow at a CAGR of 13.8% (2024-2033).

List the key industry players of the CAR-T Cell Therapies market?

Juno Therapeutics Inc., Bristol-Myers Squibb Company, Bluebird Bio Inc., Gilead Sciences Inc., Merck & Co. Inc., Pfizer Inc., Sorrento Therapeutics Inc., Merck KGaA, Amgen Inc., Eureka Therapeutics Inc., Calyxt Inc., Autolus Therapeutics, CARsgen Therapeutics Co.Ltd., Poseida Therapeutics Inc., Fortress Biotech Inc.

Which region is more appealing for vendors employed in the CAR-T Cell Therapies market?

North America is expected to account for the highest revenue share of 61.49% and boasting an impressive market value of USD 1.8 billion. Therefore, the CAR-T Cell Therapies industry in North America is expected to garner significant business opportunities over the forecast period.

Name the key areas of business for CAR-T Cell Therapies?

The US, Canada, India, China, UK, Japan, & Germany are key areas of operation for the CAR-T Cell Therapies Market.

CAR-T Cell Therapies Market Size, Share

Global CAR-T Cell Therapies Market By Drug Type (Axicabtagene Cilolecucel, Tisagenlecleucel, Brezucabtagene Autoleucel, Brexucabtagene Autoleucel, Lisocabtagene Maraleucel), By Modality (Research and Commercialized), By Target Antigen (CD19, CD22, BCMA, and Others), By Indication, By End-User, By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2024-2033

- Get a FREE Sample -

Our Clients